Screener
Castle Biosciences CSTL Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from exercise of common stock options | 322 | 18 |
| Payment of employees’ taxes on vested restricted stock units and performance-based restricted stock units | (6,598) | (2,515) |
| Proceeds from contributions to the employee stock purchase plan | 1,267 | 970 |
| Repayment of principal portion of finance lease liabilities | (24) | (26) |
| Net cash used in financing activities | (5,033) | (1,553) |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | (52,965) | (30,020) |
| Beginning of period | 116,729 | 119,709 |
| End of period | $63,764 | $89,689 |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's cash & equivalents?
- Castle Biosciences (CSTL) reported cash & equivalents of $63.76M in Q1 2026.
- How has Castle Biosciences's cash & equivalents changed year-over-year?
- Castle Biosciences's cash & equivalents decreased by 28.9% year-over-year, from $89.69M to $63.76M.
- What is the long-term trend for Castle Biosciences's cash & equivalents?
- Over 5 years (2020 to 2025), Castle Biosciences's cash & equivalents has grown at a -22.2% compound annual growth rate (CAGR), from $409.85M to $116.73M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Castle Biosciences's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude